mirtazapine (Remeron) is an atypical antidepressant often chosen when anxiety is accompanied by significant insomnia, poor appetite, or weight loss. It's sedating at low doses (7.5 to 15 mg) and antidepressant at higher doses (30 to 45 mg). Common effects include weight gain and morning grogginess. It's a reasonable option for patients who haven't tolerated SSRIs or who present with the anxious-depressed-not-sleeping-not-eating cluster.
Mirtazapine occupies a specific niche in anxiety treatment. It isn't the first medication tried for most patients, but it solves a particular clinical problem that other medications often don't.
What mirtazapine is
Mirtazapine, marketed as Remeron, is sometimes called a "noradrenergic and specific serotonergic antidepressant" (NaSSA). The pharmacology is unusual: it blocks alpha-2 adrenergic autoreceptors (which increases release of norepinephrine and serotonin), blocks serotonin 5-HT2 and 5-HT3 receptors (which is associated with anxiolytic and antiemetic effects), and blocks histamine H1 receptors (which produces sedation).
It's FDA-approved for major depressive disorder. It's used widely off-label for anxiety, particularly when anxiety coexists with depression, insomnia, or poor appetite.
The dose paradox
A pharmacologic quirk worth understanding. At low doses (7.5 to 15 mg), mirtazapine is more sedating than at higher doses (30 to 45 mg). The reason is that the histamine-blocking (sedating) effect saturates at low doses, while the noradrenergic (activating) effect builds at higher doses and partially counterbalances the sedation.
The clinical implication: a patient prescribed 7.5 mg for sleep will be more sedated than a patient on 30 mg for depression. If a patient is too sedated at a low dose, the answer is often to increase the dose, not lower it. This is counterintuitive and worth knowing.
What it feels like
The most common subjective experience is improved sleep within the first few days, followed by increased appetite within the first week or two. The antidepressant and antianxiety effects develop over four to six weeks at a therapeutic dose, similar to SSRIs.
Patients often describe feeling more grounded and less reactive on a working dose. The sleep improvement is often substantial, many patients with chronic insomnia describe their first full nights of sleep in years.
When it's chosen
Several specific situations where mirtazapine is a strong fit:
Anxious depression with significant insomnia. A patient who can't sleep and can't eat is poorly served by an SSRI alone, which often takes weeks to help with either while producing early side effects that include nausea and sleep disruption. Mirtazapine addresses the sleep and appetite first.
Older adults with anxiety, insomnia, and weight loss. A common geriatric picture where mirtazapine fits well. Weight gain is usually a welcome side effect rather than a problem.
SSRI non-responders or non-tolerators. Patients who haven't tolerated SSRI side effects (nausea, sexual side effects, sleep disruption) sometimes do well on mirtazapine, which has a different side effect profile. The standard pharmacology of SSRIs and CBT is the usual first-line picture; mirtazapine sits one step downstream.
Palliative care. Mirtazapine is widely used in palliative settings for the combination of low mood, poor appetite, sleep disruption, and nausea.
Patients who have tried SSRIs and need augmentation. Mirtazapine is sometimes added to an SSRI for partial responders, particularly when sleep remains a problem.
What it doesn't do
Mirtazapine isn't a fast-acting anxiolytic in the way benzodiazepines or hydroxyzine are. Individual doses don't produce immediate calm; the therapeutic effect develops over weeks.
It isn't typically used for OCD or PTSD, where SSRIs and trauma-focused therapy have stronger evidence.
It doesn't work as well for the patient whose main complaint is racing daytime anxiety without sleep or appetite issues. SSRIs are usually more useful in that picture.
Typical dosing and the timeline
A common starting dose is 15 mg at bedtime, with the option to increase to 30 mg after a week or two. Some clinicians start at 7.5 mg, particularly in older adults or when sedation is the main concern. The therapeutic dose for depression and anxiety is usually 30 to 45 mg.
Sleep effects appear within the first few days. Appetite effects appear within the first week or two. Antidepressant and antianxiety effects develop over four to six weeks.
Side effects and cautions
Weight gain. The most predictable side effect. Many patients gain meaningful weight, particularly in the first six months. For patients with anxiety-related weight loss, this is welcome; for others, it's a reason to consider alternatives.
Morning sedation. Common in the first week or two and usually settles. Taking the dose earlier in the evening (8 to 9 pm rather than at bedtime) often reduces morning grogginess.
Restless legs. A subset of patients develop restless legs syndrome on mirtazapine, particularly at higher doses. If this occurs, switching to a different medication is usually preferable.
Anticholinergic effects. Less than first-generation antihistamines, but present. Dry mouth, mild constipation, occasional dizziness.
Drug interactions. Mirtazapine has fewer drug interactions than many antidepressants. It doesn't significantly inhibit cytochrome P450 enzymes.
Discontinuation. Mirtazapine produces a milder discontinuation syndrome than SSRIs or SNRIs but should still be tapered rather than stopped abruptly after sustained use.
External citations
The DailyMed mirtazapine label is the authoritative source. The APA practice guideline for depression discusses mirtazapine's place among antidepressants.